Ultrasound Quadratus Lumborum Block Vs Fascia Iliaca Block in Pediatrics Undergoing Hip Surgery .

Sponsor
Cairo University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05282849
Collaborator
(none)
30
1
2
2.4
12.7

Study Details

Study Description

Brief Summary

Comparison between ultrasound guided transmuscular QL block and Fascia iliaca block in pediatric patients undergoing DDH surgery regarding the quality of pain control in the perioperative period..

Condition or Disease Intervention/Treatment Phase
  • Procedure: ultrasound guided fascia iliaca block
  • Procedure: ultrasound guided quadratus lumborum block
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Ultrasound Guided Quadratus Lumborum Block Versus Fascia Iliaca Block in Pediatric Patients Undergoing Developmental Dysplasia of Hip Surgical Repair. A Randomized Comparative Study
Actual Study Start Date :
Apr 4, 2022
Anticipated Primary Completion Date :
Jun 1, 2022
Anticipated Study Completion Date :
Jun 15, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Group F: ultrasound guided fascia iliaca block group

Procedure: ultrasound guided fascia iliaca block
ultrasound guided fascia iliaca block anesthetizes variable combinations of the femoral nerve , lateral femoral cutaneous nerve , and obturator nerve, and is effective for many painful hip surgeries making it potentially useful for analgesia following Developmental Dysplasia of Hip (DDH) surgery.

Active Comparator: Group Q: ultrasound guided quadratus lumborum block group

Procedure: ultrasound guided quadratus lumborum block
ultrasound-guided quadratus lumborum (QL) block provides perioperative somatic, even visceral analgesia for patients including pediatrics, undergoing abdominal or hip surgery. The local anesthetic injected adjacently into the quadrates lumborum muscle spreads in a medial and cranial direction under the crura and arcuate ligaments of the diaphragm, then into the thoracic paravertebral space anesthetizing the hip region

Outcome Measures

Primary Outcome Measures

  1. Total 12 hours postoperative opioid consumption [from the time of transfer of the patient to the pacu at one hour intervals for 12 hours]

    amount of morphine consumed as rescue analgesia in first 12 hours

Secondary Outcome Measures

  1. Postoperative pain using Face, Legs, Activity, Cry, Consolability scale (FLACC ) pain rating scale [from the time of transfer to the PACU, every hour for the first 24 hours postoperative]]

    pain score of paitients in the post operative period

  2. Side effects [from the time of transfer to the PACU, for the first 24 hours postoperative]

    respiratory depression and postoperative nausea and vomiting

  3. Total 24 hours postoperative opioid consumption [from the time of transfer of the patient to the pacu at one hour intervals for 24hours]

    amount of morphine consumed as rescue analgesia in first 24hours

Eligibility Criteria

Criteria

Ages Eligible for Study:
2 Years to 12 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Children aged 2-12 years

  • Of both sexes

  • American society of anesthesiologist (ASA) physical status classification class I

  • Undergoing general anaesthesia for DDH surgery

Exclusion Criteria:
  • Parents' refusal of regional block

  • Duration of surgery over 120 min.

  • History of allergy to local anesthetics

  • Bleeding disorders (INR >1.4, Platelet count< 75000)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Faculty of medicine Cairo university Cairo Egypt

Sponsors and Collaborators

  • Cairo University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Sherif Mohamed Abd El Moneim Soaida, MD, assistant professor, Cairo University
ClinicalTrials.gov Identifier:
NCT05282849
Other Study ID Numbers:
  • SMS2022-1
First Posted:
Mar 16, 2022
Last Update Posted:
Apr 15, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Sherif Mohamed Abd El Moneim Soaida, MD, assistant professor, Cairo University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 15, 2022